Eluxadoline-induced pancreatitis occurring in an adult man without a prior cholecystectomy.

Author: GroffAndrew, JainRohit, PackardElizabeth, ShahidZainab

Paper Details 
Original Abstract of the Article :
Eluxadoline is a novel medication that was approved in the USA in 2015 for the treatment of diarrhoea-predominant irritable bowel syndrome. Due to its unique mechanism of action as both an opioid agonist and antagonist, it has been placed as a schedule IV controlled substance. Since its approval, th...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6720687/

データ提供:米国国立医学図書館(NLM)

Eluxadoline-induced Pancreatitis: A Case Report and Review

This study presents a rare case of eluxadoline-induced pancreatitis in an adult man without prior cholecystectomy. The authors highlight the importance of understanding the potential risks associated with this medication, even in patients who do not have a history of gallbladder removal. The study underscores the need for careful monitoring and appropriate precautions when prescribing eluxadoline.

Eluxadoline: A Potential Risk Factor for Pancreatitis

This study, like a lone camel navigating a perilous desert, highlights the unexpected and serious side effects of eluxadoline, a medication approved for the treatment of diarrhea-predominant irritable bowel syndrome. The case report, like a warning beacon in the vast landscape of gastrointestinal health, underscores the importance of careful patient selection and close monitoring when prescribing this medication. The authors emphasize the need for ongoing research to better understand the mechanisms underlying eluxadoline-induced pancreatitis and develop strategies for minimizing these risks.

Eluxadoline: Balancing Benefits and Risks

This study, like a compass guiding us through the complexities of gastrointestinal disorders, reminds us that every medication comes with potential risks and benefits. The authors emphasize the importance of a careful evaluation of each patient's medical history and risk factors before prescribing eluxadoline. By understanding the potential risks associated with this medication, clinicians can make informed decisions about its use, ensuring the safety and well-being of their patients.

Dr.Camel's Conclusion

This study, like a camel caravan traversing a vast and unforgiving desert, highlights the unexpected dangers of eluxadoline, a medication approved for the treatment of irritable bowel syndrome. The researchers, like skilled desert guides, emphasize the importance of understanding the potential risks associated with medications, even those used for seemingly benign conditions. The study's findings serve as a reminder that every medication, like every step in the desert, requires careful consideration and vigilance. By working together, we can create a more navigable landscape for those seeking relief from digestive disorders, ensuring their safety and well-being along the way.

Date :
  1. Date Completed 2020-02-18
  2. Date Revised 2021-08-29
Further Info :

Pubmed ID

31466958

DOI: Digital Object Identifier

PMC6720687

Related Literature

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.